Lupus Science & Medicine

Papers
(The H4-Index of Lupus Science & Medicine is 20. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Outcomes following immunosuppressive therapy withdrawal after complete renal response in proliferative lupus nephritis178
Mortality patterns of SLE and the associated risk factors in Korean patients: a nationwide cohort study49
COVID-19 vaccination questionnaire in patients with systemic lupus erythematosus: an observational study46
Safety, immunological effects and clinical response in a phase I trial of umbilical cord mesenchymal stromal cells in patients with treatment refractory SLE40
Scleroderma-like capillaroscopic pattern in SLE is not a sign of overlap syndrome in both adults and children40
One-third of patients with lupus nephritis classified as complete responders continue to accrue progressive renal damage despite resolution of proteinuria39
Intermittent and Persistent Type 2 lupus: patient perspectives on two distinct patterns of Type 2 SLE symptoms37
Nailfold capillary scleroderma pattern may be associated with disease damage in childhood-onset systemic lupus erythematosus: important lessons from longitudinal follow-up32
Comparison of short interval and low dose (SILD) with high dose of cyclophosphamide in the susceptibility to infection in SLE: a multicentrereal-world study32
B lymphocytes in treatment-naive paediatric patients with lupus are epigenetically distinct from healthy children29
Association of one-point glucocorticoid-free status with chronic damage and disease duration in systemic lupus erythematosus: a cross-sectional study27
Risks of mortality and severe coronavirus disease 19 (COVID-19) outcomes in patients with or without systemic lupus erythematosus27
Novel multiclass classification machine learning approach for the early-stage classification of systemic autoimmune rheumatic diseases26
COVID-19 prognosis in systemic lupus erythematosus compared with rheumatoid arthritis and spondyloarthritis: results from the CONTROL-19 Study by the Italian Society for Rheumatology26
Value of SLE-DAS in assessing disease activity in patients with systemic lupus erythematosus: a single-centre retrospective study23
Antiplatelet effects of hydroxychloroquine in patients with systemic lupus erythematosus evaluated by the total thrombus-formation analysis system (T-TAS)23
Clinical implications of discordance between anti-dsDNA antibodies by multiplex flow immunoassay andCrithidia luciliaeassay in a multiethnic racial cohort of patients with SLE22
High-density lipoprotein cholesterol subfraction HDL2 is associated with improved endothelial function in systemic lupus erythematosus22
High-dimensional analysis of T-cell profiling variations following belimumab treatment in systemic lupus erythematosus22
Patients achieving low lupus disease activity state, systemic lupus erythematosus disease control or remission showed lower rates of organ damage during longitudinal follow-up: analysis of the Hopkins20
Development and psychometric evaluation of a physician global assessment for type 2 systemic lupus erythematosus symptoms20
0.42202091217041